This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
Not specified.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The clinical probabilities were extracted from at least 11 published papers.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The results of the review are as follows: the percentage of named male and female partners receiving treatment was (range in parentheses) 0.67 (0.67-0.97) and 0.55 (0.55-0.97),respectively; the percentage of male and female partners presenting and testing positive was 0.37 (0.35-0.75)and 0.58 (0.25-0.65), respectively; the percentage of untreated initial and recurrent C. trachomatis infected women who will develop PID was 0.20 (0.15-0.40) and 0.30, respectively; the percentage of infected male partners being asymptomatic was 0.43 (0.25-0.86); the percentage of infected male partners being symptomatic who do not seek care in the absence of intervention was 0.05; the percentage of female reinfection in the absence of intervention was 27%.
Measure of benefits used in the economic analysis
The decision model was used to estimate the measures of benefits including expected cases of PID per 1,000 index patients and cases of PID prevented per 1,000 index patients.
Direct costs
The costs were discounted. Quantities were not reported separately from the costs. The cost items were reported separately. The total cost consisted of the direct programme (partner notification (PN))costs including cost of PN interview and cost of locating one partner, and direct medical costs including cost of PID weighted by sequelae and public clinic cost for one dose of azithromycin. The total cost per 1000 index patients and cost saved (incremental costs) by PN per 1000 index patients were reported. Cost calculations were performed adopting a health care system perspective. The cost data were extracted from studies published between 1986 and 1995. 1994 price data were used.
